Acitretin in psoriasis: An evolving scenario

International Journal of Dermatology

Volumn 53, Issue 5, 2014, Pages 525-538

  Dogra, Sunil ^a   Yadav, Savita ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; LIPID; LIVER ENZYME; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR;

ANOPHTHALMIA; ARTHRALGIA; BLEEDING; BRAIN PSEUDOTUMOR; CALCIFICATION; CAPILLARY LEAK SYNDROME; CARDIOVASCULAR MALFORMATION; CHILDHOOD PSORIASIS; DISEASE CONTROL; DNA SEQUENCE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; EMBRYOPATHY; ENCEPHALOMENINGOCELE; ERYTHEMA; ERYTHRODERMIC PSORIASIS; FACE DYSMORPHIA; GENERALIZED PUSTULAR PSORIASIS; HIP MALFORMATION; HUMAN; HYPEROSTOSIS; LIMIT OF DETECTION; LIPID BLOOD LEVEL; LIVER TOXICITY; LOW SET EAR; MAINTENANCE THERAPY; MENINGOMYELOCELE; MONOTHERAPY; MYALGIA; NAIL PSORIASIS; OPEN STUDY; OSTEOPOROSIS; PALMOPLANTAR PUSTULAR PSORIASIS; PAPILLEDEMA; PATHOGENESIS; PATIENT COUNSELING; PATIENT MONITORING; PATIENT SELECTION; PERIPHERAL EDEMA; PHOTOCHEMOTHERAPY; PROMOTER REGION; PSORIASIS; PUSTULAR PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULOPATHY; REVIEW; SIDE EFFECT; SKIN PIGMENTATION; SUICIDAL BEHAVIOR; SYNOSTOSIS; SYSTEMATIC REVIEW; DRUG COMBINATION;

ACITRETIN; DRUG THERAPY, COMBINATION; HUMANS; PSORIASIS;

EID: 84899479662     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12365     Document Type: Review

References (95)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
2. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 2012; 133: 17-26.
3. Orfanos CE. Treatment of psoriasis with retinoids: present status. Cutis 1999; 64: 347-353.
4. Lee CS, Li K. A review of acitretin for the treatment of psoriasis. Expert Opin Drug Saf 2009; 8: 769-779.
5. Booij MT, Van De Kerkhof PC. Acitretin revisited in the era of biologics. J Dermatolog Treat 2011; 22: 86-89.
6. Sbidian E, Maza A, Montaudié H, et al. Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review. J Eur Acad Dermatol Venereol 2011; 25(Suppl. 2): 28-33.
7. McNamara PJ, Jewell RC, Jensen BK, et al. Food increases the bioavailability of acitretin. J Clin Pharmacol 1988; 28: 1051-1055.
8. Brindley CJ. An overview of recent clinical pharmacokinetic studies with acitretin. Dermatolgica 1989; 178: 79-87.
9. Chou RC, Wyss R, Huselton CA, et al. A potentially new metabolic pathway: ethyl esterification of acitretin. Xenobiotica 1992; 8: 993-1002.
10. Larsen FG. Pharmacokinetics of etretinate and acitretin with special reference to treatment of psoriasis. Acta Derm Venereol 1995; 190: 1-33.
11. Petkovich M, Brand NJ, Krust A, et al. Identification of a second human retinoic acid receptor. Nature 1988; 332: 850-853.
12. Siegenthaler G, Gumovski-Sunek D, Saurat JH. Metabolism of natural retinoids in psoriatic epidermis. J Invest Dermatol 1990; 95: S47-S48.
13. Orfanos CE, Zouboulis CC, Almond-Roesler B, et al. Current use and future potential role of retinoids in dermatology. Drugs 1997; 53: 358-388.
14. Tong PS, Horowitz NN, Wheeler LA. Trans retinoic acid enhances the growth response of epidermal keratinocyte to epidermal growth factor and transforming growth factor beta. J Invest Dermatol 1990; 94: 126-131.
15. Warren RB, Griffiths CE. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol 2008; 26: 438-447.
16. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-485.
17. Kragballe K, Jansen CT, Geiger J-M, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis: results of a Nordic multicentre study. Acta Derm Venereol 1989; 69: 35-40.
18. Ledo A, Martin M, Geiger JM, et al. Acitretin (Ro 10-1670) in the treatment of severe psoriasis. A randomized double-blind parallel study comparing acitretin and etretinate. Int J Dermatol 1988; 27: 656-660.
19. Gollnick H, Bauer R, Brindley C, et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 1988; 3: 458-468.
20. Meffert H, Sonnichsen N. Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate. Acta Derm Venereol Suppl (Stockh) 1989; 146: 176-177.
21. Goldfarb MT, Ellis CN, Gupta AK, et al. Acitretin improves psoriasis in dose dependent fashion. J Am Acad Dermatol 1988; 18: 655-662.
22. Olsen EA, Weed WW, Meyer CJ, et al. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989; 21: 681-686.
23. Torok L, Kadar L, Geiger JM. Acitretin treatment of severe psoriasis. Acta Dermatol Venereol Suppl (Stockh) 1989; 146: 104-106.
24. Berbis P, Geiger JM, Vaisse C, et al. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 1989; 178: 88-92.
25. Dogra S, Jain A, Kanwar AJ. Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study. J Eur Acad Dermatol Venereol 2012. [Epub ahead of print]
26. Lassus A, Geiger JM, Nyblom M, et al. Treatment of severe psoriasis with etretin (Ro 10-1670). Br J Dermatol 1987; 117: 333-341.
27. Geiger JM, Czarnetzki BM. Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica 1988; 176: 182-190.
28. Murray HE, Anhalt AW, Lessard R, et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicentre trial. J Am Acad Dermatol 1991; 24: 598-602.
29. Rosenbach M, Hsu S, Korman NJ, et al. National Psoriasis Foundation Medical Board. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62: 655-662.
30. Takahashi MDF, Castro LG, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol 2007; 157: 828-831.
31. Wolska H, Jablonska S, Langner A, et al. Etretinate therapy in generalized pustular psoriasis (Zumbusch type) Immediate and long-term results. Dermatologica 1985; 171: 297-304.
32. Ozawa A, Ohkido M, Haruki Y, et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol 1999; 26: 141-149.
33. White SI, Marks JM, Shuster S. Etretinate in pustular psoriasis of palms and soles. Br J Dermatol 1985; 113: 581-585.
34. Foged E, Holm P, Larsen PO, et al. A randomized trial of etretinate (Tigason) in palmoplantar pustulosis. Dermatologica 1983; 166: 220-223.
35. Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988; 119: 755-759.
36. Ettler K, Richards B. Acitretin therapy for palmoplantar pustulosis combined with UVA and topical 8-MOP. Int J Dermatol 2001; 40: 541-542.
37. Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg 2003; 7: 317-321.
38. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1-27.
39. Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269-271.
40. López V, Molina I, Martí N, et al. Severe nail psoriasis with a rapid response to acitretin. Clin Exp Dermatol 2009; 34: e332-e333.
41. Ormerod AD, Campalani E, Goodfield MJ. BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010; 162: 952-963.
42. Prendiville J, Bingham EA, Burrows D. Premature epiphyseal closure - a complication of etretinate therapy in children. J Am Acad Dermatol 1986; 15: 1259-1262.
43. Halkier-Sorensen L, Andresen J. A retrospective study of bone changes in adults treated with etretinate. J Am Acad Dermatol 1989; 20: 83-87.
44. Ruiz-Maldonado R, Tamayo L. Retinoids in disorders of keratinization: their use in children. Dermatologica 1987; 175(Suppl. 1): 125-132.
45. Ergin S, Ersoy-Evans S, Sahin S, et al. Acitretin is a safe treatment option for infantile pustular psoriasis. J Dermatolog Treat 2008; 19: 341-343.
46. Kopp T, Karlhofer F, Szépfalusi Z, et al. Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type. Br J Dermatol 2004; 151: 912-916.
47. Lebwohl M, Menter A, Koo J, et al. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004; 50: 416-430.
48. Ashcroft DM, Li Wan Po A, Williams HC, et al. Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability. Arch Dermatol 2000; 136: 1536-1543.
49. Rim JH, Park JY, Choe YB, et al. The efficacy of calcipotriol + acitretin combination therapy for psoriasis: comparison with acitretin monotherapy. Am J Clin Dermatol 2003; 4: 507-510.
50. Lowenthal KE, Horn PJ, Kal RE. Concurrent use of methotrexate and acitretin revisited. J Dermatolog Treat 2008; 19: 22-26.
51. van de Kerkhof PC, de Rooij MJ. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. Br J Dermatol 1997; 136: 275-278.
52. Yamauchi PS, Rizk D, Lowe NJ. Retinoid therapy for psoriasis. Dermatol Clin 2004; 22: 467-476.
53. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther 2010; 23: 137-143.
54. Mittal R, Malhotra S, Pandhi P, et al. Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 2009; 145: 387-393.
55. Saurat JH, Geiger JM, Amblard P, et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA, and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 1988; 177: 218-224.
56. Tanew A, Guggenbichler A, Hönigsmann H, et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991; 25: 682-684.
57. Sommerburg C, Kietzmann H, Eichelberg D, et al. Acitretin in combination with PUVA: a randomized double-blind placebo-controlled study in severe psoriasis. J Eur Acad Dermatol Venereol 1993; 2: 308-317.
58. Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989; 120: 665-670.
59. Ruzicka T, Sommerburg C, Braun-Falco O, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 1990; 126: 482-486.
60. Kampitak T, Asawanonda P. The efficacy of combination treatment with narrowband UVB (TL-01) and acitretin vs narrowband UVB alone in plaque-type psoriasis: a retrospective study. J Med Assoc Thai 2006; 89(Suppl. 3): S20-S24.
61. Spuls PI, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. J Dermatolog Treat 2003; 14: 17-20.
62. Ozdemir M, Engin B, Baysal I, et al. A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis. Acta Derm Venereol 2008; 88: 589-593.
63. Otley CC, Stasko T, Tope WD, et al. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006; 32: 562-568.
64. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933-1938.
65. Muchenberger S, Schöpf E, Simon JC. The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis. Br J Dermatol 1997; 137: 587-589.
66. Lowe N, Prystowsky JH, Bourget T, et al. Acitretin plus UVB therapy for psoriasis: comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991; 24: 591-594.
67. Lebwohl M, Drake L, Menter A, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001; 45: 544-553.
68. Conley J, Nanton J, Dhawan S, et al. Novel combination regimens: biologics and acitretin for the treatment of psoriasis - a case series. J Dermatolog Treat 2006; 17: 86-89.
69. Gisondi P, Del Giglio M, Cotena C, et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008; 158: 1345-1349.
70. Smith EC, Riddle C, Menter MA, et al. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol 2008; 47: 514-518.
71. Philipp S, Wilsmann-Theis D, Weyergraf A, et al. Combination of adalimumab with traditional systemic antipsoriatic drugs - a report of 39 cases. J Dtsch Dermatol Ges 2012; 10: 821-837.
72. Menter MA, See JA, Amend WJ, et al. Proceedings of the psoriasis combination and rotation therapy conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol 1996; 34: 315-321.
73. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999; 41: S25-S28.
74. Aydogan K, Karadogan SK, Tunali S. Acitretin-induced subungual hemorrhage. Int J Dermatol 2007; 46: 494-495.
75. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999; 41: S7-S12.
76. Geiger JM, Walker M. Is there a reproductive safety risk in male patients treated with acitretin (Neotigason/Soriatane)? Dermatology 2002; 205: 105-107.
77. Pearce DJ, Klinger S, Ziel KK, et al. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol 2006; 142: 1000-1004.
78. Vahlquist C, Selinus I, Vessby B. Serum-lipid changes during acitretin (etretin) treatment of psoriasis and palmoplantar pustulosis. Acta Derm Venereol (Stockh) 1988; 68: 300-305.
79. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007; 29: 1354-1367.
80. Halkier-Sorensen L, Laurberg G, Andresen J. Bone changes in children on long-term treatment with etretinate. J Am Acad Dermatol 1987; 16: 999-1006.
81. van Dooren-Greebe RJ, Lemmens JA, De Boo T, et al. Prolonged treatment with oralretinoids in adults: no influence on the frequency and severity of spinal abnormalities. Br J Dermatol 1996; 134: 71-76.
82. Lee E, Koo J. Single-center retrospective study of long-term use of low-dose acitretin (Soriatane) for psoriasis. J Dermatolog Treat 2004; 15: 8-13.
83. Mørk NJ, Kolbenstvedt A, Austad J. Efficacy and skeletal side effects of two years' acitretin treatment. J Cutan Med Surg 2006; 10: 291-299.
84. McMullen EA, McCarron P, Irvine AD, et al. Association between long-term acitretin therapy and osteoporosis: no evidence of increased risk. Acta Derm Venereol 1992; 72: 445-448.
85. Van de Kerkhof PC. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther 2006; 19: 252-263.
86. Starling J 3rd, Koo J. Evidence based or theoretical concern? Pseudotumor cerebri and depression as acitretin side effects. J Drugs Dermatol 2005; 4: 690-696.
87. Hayes J, Koo J. Depression and acitretin: a true association or a class labeling? J Drugs Dermatol 2011; 10: 409-412.
88. Vahlquist A. Long-term safety of retinoid therapy. J Am Acad Dermatol 1992; 27: S29-S33.
89. Pang ML, Murase JE, Koo J. An updated review of acitretin - a systemic retinoid for the treatment of psoriasis. Expert Opin Drug Metab Toxicol 2008; 4: 953-964.
90. Tey HL, Theng TS. Acitretin induced bipedal edema. J Dermatol 2006; 33: 372-374.
91. Arican O, Sasmaz S, Ozbulut O. Increased suicidal tendency in a case of psoriasis vulgaris under acitretin treatment. J Eur Acad Dermatol Venereol 2006; 20: 464-465.
92. Lois N, White M. Acitretin-associated maculopathy. Arch Ophthalmol 2004; 122: 928-930.
93. Vos LE, Vermeer MH, Pavel S. Acitretin induces capillary leak syndrome in a patient with pustular psoriasis. J Am Acad Dermatol 2007; 56: 339-342.
94. Bastos PR, Avelleira JC, Cruz MA, et al. Granulation tissue in palpebral conjunctivae associated with acitretin therapy. J Am Acad Dermatol 2008; 58(2 Suppl): S41-S42.
95. Seckin D, Yildiz A. Repigmentation and curling of hair after acitretin therapy. Australas J Dermatol 2009; 50: 214-216.